## LONGITUDINAL VARIATION OF FIBROGLANDULAR TISSUE AND BACKGROUND PARENCHYMAL ENHANCEMENT ON BREAST MRI IN HIGH-RISK WOMEN: A QUANTITATIVE ASSESSMENT

Shandong Wu<sup>1</sup>, Wendie A. Berg<sup>2</sup>, Margarita L. Zuley<sup>2</sup>, Jules Sumkin<sup>2</sup>, Rachel C. Jankowitz<sup>3</sup>, and David Gur<sup>4</sup>

<sup>1</sup>Radiology, University of Pittsburgh, Pittsburgh, PA, United States, <sup>2</sup>Radiology, University of Pittsburgh Medical Center Magee-Womens Hospital, PA, United States, <sup>3</sup>Oncology, University of Pittsburgh Medical Center Magee-Womens Hospital, PA, United States, <sup>4</sup>Radiology, University of Pittsburgh, PA, United States

TARGET AUDIENCE: Radiologists, oncologists, and quantitative scientists interested in imaging biomarkers for breast cancer risk assessment.

PURPOSE: Screening breast MRI is recommended for women at high risk (lifetime risk ≥20%-25%) of developing breast cancer. Recent studies have shown that the fibroglandular tissue volume (FGT) and background parenchymal enhancement (BPE) seen in breast MRI may be predictive of breast cancer risk ¹ and are potential intervention-response biomarkers for risk-reducing salpingo-oophorectomy ². The purpose of this pilot study is to perform quantitative assessment on the longitudinal variation of FGT volume and BPE volume in sequential breast MRI scans for a cohort of high-risk women who did not undergo any specific risk-reduction intervention.

METHODS: We retrospectively identified 71 high-risk women in our high-risk screening program. For each participant we collected two longitudinal cancer-free MRI scans acquired at two time points (TPs) (TP1: early scan; TP2: later scan; the mean ( $\pm$ SD) of the temporal gap between TP1 and TP2 was 519 $\pm$ 282 days, min=166 days and max=1613 days; the mean ( $\pm$ SD) of age is 45.0 $\pm$ 8.5 years at TP1 and 46.6 $\pm$ 8.8 years at TP2). A fully automated computerized methodology pipeline <sup>2-4</sup> was adapted to compute the FGT in the dynamic contrast enhanced (DCE) pre-contrast images and the BPE in the fourth DCE subtraction images (subtraction = post-contrast – pre-contrast) (Fig. 1). In total, 142 MRI scans were processed. For each scan, three quantitative measures are produced by the computerized methods: (1) volume of FGT (|FGT|); (2) volume of the enhancement detected over the whole breast (|BPE<sub>b</sub>|); and, (3) volume of the enhancement detected over the FGT area only (|BPE<sub>f</sub>|). For each measure, the mean ( $\pm$ SD) across scans at TP1 and TP2 was compared using a paired *t*-test for significance. The difference between paired values measured respectively at TP2 and TP1 (i.e.,  $X_{TP2}$  -  $X_{TP1}$ ) was compared to show the temporal variation for each of the 71 women.




Fig. 1: FGT and BPE estimation. a. Whole-breast segmentation (red). b. FGT estimation (green). c. The fourth DCE subtraction image (SUB 4). d. BPE estimated on the whole-breast (BPE<sub>b</sub>) area in SUB 4 image. e. BPE estimated on the FGT area only (BPE<sub>f</sub>) in SUB 4 image.

RESULTS: Five women in the study cohort were diagnosed with breast cancer with an average of 432±188 days follow-up after TP2. The variation of each measure was analyzed for three subgroups: full cohort (N=71), cancer (N=5), and non-cancer (N=66). No significant change (all p>0.05) was observed in both |FGT| and |BPE<sub>f</sub>| for all three subgroups. However, there appears to be significant increase in the measure of |BPE<sub>b</sub>| in the full cohort (p=0.02) as well as the non-cancer group (p=0.03), albeit, not in the group of 5 cancer patients (p=0.3). Furthermore, based on the paired differences in the three measures (Fig. 2), it appears that from TP1 to TP2, |BPE<sub>b</sub>| increases for the three invasive cancer cases (i.e., ILC and IDC) while it decreases for the two cases of less-aggressive cancer (i.e., DCIS). At the same time, we also observe a large increase in |BPE<sub>b</sub>| at TP2 for several non-cancer participants (no breast cancer diagnosed at the time of the study).




Fig. 2: Paired difference (X<sub>TP2</sub> - X<sub>TP1</sub>) in the three measures, i.e., |FGT| (left), |BPE<sub>b</sub>| (middle), and |BPE<sub>f</sub>| (right), for each woman of the study cohort.

DISCUSSION: The assessment of enhancement occurring only in the FGT area (i.e.,  $|FGT_f|$ ) is more relevant in clinic as in principle primarily FGT is expected to enhance. While there is no significant change in both |FGT| and  $|FGT_f|$  within the time studied (i.e., TP2 - TP1), which is as expected, the observed significant variation in  $|BPE_b|$  indicates that  $|BPE_b|$  may capture certain properties that reflect biological differences (e.g., vasculature) in the non-FGT (fatty) area over time. In addition, although invasive cancer and DCIS may be separated by the paired differences in  $|BPE_b|$ , this finding should be interpreted quite cautiously because of the limited number of cancer cases and the observed increase in  $|BPE_b|$  in several non-cancer women as well.

CONCLUSION: The preliminary results demonstrate the temporal variability of FGT and BPE, which may be useful as a reference measure when investigating these parameters as risk predictors and possibly as indicators of intervention-response in high-risk women.

REFERENCES:

- 1. King V, et al., Background parenchymal enhancement at breast MR imaging and breast cancer risk, Radiology 260(1), 50-60 (2011).
- 2. Wu S, et al., Effect of risk-reducing salpingo-oophorectomy on breast MRI fibroglandular tissue and background parenchymal enhancement in BRCA1/2 mutation carriers: a quantitative assessment, ISMRM 2013 (Oral Presentation).
- 3. Wu S. et al., Automated fibroglandular tissue segmentation and volumentric density estimation in breast MRI. Med. Phy. (In press).
- 4. Wu S, et al., Automated chest wall line detection for whole-breast segmentation in sagittal breast MR images, Med. Phy., 40:4, 042301-12 (2013).